MedTrace Logo

Cilostazol Following Peripheral Endovascular Procedures

NCT02770274 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2021-01-12

No results posted yet for this study

Summary

To compare the safety and effectiveness of dual anti-platelet therapy with cilostazol 100 mg twice daily and aspirin 100 mg daily versus monotherapy with aspirin 100 mg daily in patients undergoing peripheral angioplasty or stenting or both for the management of peripheral arterial disease.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Cilostazol

Dual therapy with Cilostazol 100 mg twice daily

DRUG

Aspirin

Monotherapy with aspirin 100 mg once daily

Sponsors & Collaborators

  • University Hospital of Patras

    collaborator OTHER

  • Attikon Hospital

    lead OTHER

Principal Investigators

  • Elias Brountzos, MD, PhD, EBIR · 2nd Department of Radiology, Interventional Radiology Unit, National and Kapodestrian University of Athens, Attikon University General Hospital, Athens, Greece.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02770274 on ClinicalTrials.gov